GT Biopharma Inc OXIA.BE
€5.25 €0.06 (1.16%) 1D
Last Updated: Feb 02, 12:00 AM·BE
Pricing for DE stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is GT Biopharma Inc Stock Halal?
Shariah Compliance Analysis of OXIA.BE Stock
Germany Health Care Nano Cap No. As of September 2026, GT Biopharma Inc (OXIA.BE) is classified as NOT HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. GT Biopharma Inc does not pass Musaffa's business and financial screening criteria.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
OXIA.BE Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, GT Biopharma Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
GT Biopharma Inc (OXIA.BE) Chart
Financial Metrics & Statements of GT Biopharma Inc (OXIA.BE)
FAQ's for GT Biopharma Inc (OXIA.BE)
- As of September 2026, GT Biopharma Inc OXIA.BE is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes GT Biopharma Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in GT Biopharma Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of GT Biopharma Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of GT Biopharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of GT Biopharma Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for GT Biopharma Inc (OXIA.BE)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
